Dans le même genre
Résultats du 3e trimestre 2026 d'Eli Lilly
ESTIMÉCONFIANCE 71 %dans 36 joursLilly n'a pas encore confirmé la date (aucun communiqué « Lilly confirme la date et la conférence téléphonique pour le troisième trimestre 2026 » au 22 septembre 2026 ; celui du T2 est paru le 22 juillet pour le 5 août). Public.com[2] et Nasdaq[3] indiquent la publication du T3 comme « attendue » le 29/10/2026 « avant l'ouverture du marché », ce qui correspond aux habitudes de Lilly (T3 2025 publié le 30 octobre 2025) et à ses conférences, qui « débuteront à 10 h, heure de l'Est » — soit le 29 octobre 2026 à 10:00 ET (14:00 UTC), estimation valable jusqu'au communiqué de confirmation de Lilly.Eli Lilly devrait publier ses résultats du troisième trimestre 2026 le 29 octobre, avec sa conférence téléphonique habituelle à 10 h ET. Le groupe aborde cette échéance avec une prévision de chiffre d'affaires 2026 relevée à 85-87 milliards de dollars, après un deuxième trimestre en hausse de 48 %, à 23,0 milliards, porté par Mounjaro et Zepbound.0.71La FDA approuve Inluriyo de Lilly associé à Verzenio contre le cancer du sein muté ESR1
CONFIRMÉCONFIANCE 85 %il y a 5 joursLe communiqué de Lilly porte la mention "INDIANAPOLIS, 18 septembre 2026" et indique qu'il "a annoncé aujourd'hui que la Food and Drug Administration (FDA[4]) américaine a accordé une approbation complète" ; l'avis de la FDA elle-même fixe la date d'approbation au 18 septembre 2026.Une association entièrement orale qui a doublé la survie médiane sans progression, de 5,5 à 11,1 mois, chez les patientes mutées ESR1 dans l'essai EMBER-3. C'est la deuxième approbation de la FDA pour Inluriyo en moins d'un an.0.65Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
CONFIRMÉCONFIANCE 88 %il y a 23 joursThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".[1]Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.$2.9B0.65Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out
ESTIMÉCONFIANCE 50 %dans 1,8 anClinicalTrials.gov[1] lists 2028-07-05 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.0.64Lilly Submits Retatrutide to the FDA for Approval
ESTIMÉ3 mois de retardCONFIANCE 77 %dans 189 joursLilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.[1]Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.0.62Lilly lance la construction d'une usine Foundayo de 6,5 milliards de dollars à Generation Park, Houston
CONFIRMÉCONFIANCE 84 %avant-hierLe communiqué de Lilly porte la mention "HOUSTON[4], 21 septembre 2026" et indique que Lilly "a posé la première pierre aujourd'hui à Houston, Texas[6]" ; Community Impact[2] rapporte que la cérémonie s'est tenue le 21 septembre.Une usine de 236 acres qui produira le principe actif de la pilule amaigrissante Foundayo de Lilly, avec plus de 600 emplois permanents et environ 4 000 emplois de chantier. Lilly la prévoit opérationnelle d'ici 2030.$6.5B0.61Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
CONFIRMÉCONFIANCE 87 %il y a 120 joursLilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".[1]Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.$3.8B0.61Maridebart Cafraglutide's Phase 3 Trial in Heart Failure With Preserved Ejection Fraction Reads Out
ESTIMÉCONFIANCE 50 %dans 1,8 anClinicalTrials.gov[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Amgen's phase 3 trial of Maridebart Cafraglutide in heart failure with preserved ejection fraction reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,056 participants. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.0.61Elecoglipron's Phase 3 Trial in Weight Management Reads Out
ESTIMÉCONFIANCE 50 %dans 1,9 anClinicalTrials.gov[1] lists 2028-07-31 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Elecoglipron in weight management reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,500 participants. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).0.60TSMC's Dresden Fab (ESMC) Starts Production
ESTIMÉCONFIANCE 73 %dans 1,3 anTSMC's[1][6] founding release gives a bound, not a day: "production targeted to begin by the end of 2027"; at the September 2026 topping-out the partners still said production starts in 2027 and Hardwareluxx[3] reported tool installation "bis Ende 2027", after which the first chips follow - so 31 December 2027, estimated.ESMC, TSMC's EUR 10 billion joint venture with Bosch, Infineon and NXP, is due to start production at its Dresden fab by the end of 2027 - Europe's first FinFET-capable foundry, making 28/22nm and 16/12nm chips mainly for cars and industry.€10B0.60TSMC's Dresden Fab (ESMC) Tops Out
CONFIRMÉCONFIANCE 80 %il y a 9 joursFocus Taiwan[1]: "A topping out ceremony was held Monday at the site" (dateline Sept. 14, "The ceremony, held on Sept. 14"); dpa's preview gave the time: ESMC "feiert ... am Montag (12.00 Uhr) mit einem Richtfest den Abschluss des Rohbaus" - noon CEST, 10:00 UTC.Twenty-five months after its groundbreaking, ESMC - TSMC's joint venture with Bosch, Infineon and NXP - celebrated the topping-out of its roughly EUR 10 billion chip fab in Dresden, TSMC's first in Europe. The shell is finished; cleanroom fit-out follows, with the first process tools due in the second half of 2027.€10B0.60TSMC Starts Volume Production of 2nm (N2) Chips in Kaohsiung
ESTIMÉCONFIANCE 73 %il y a 266 joursTSMC's[1][2] 2nm page says N2 "has started volume production in 4Q25 as planned" and its 2025 annual report that it "entered high volume manufacturing in 4Q'25"; neither names the day, so the quarter's last day stands in.TSMC's first nanosheet-transistor node, N2, entered volume production in the fourth quarter of 2025 as planned, starting at Fab 22 in Kaohsiung, with Fab 20 in Hsinchu as its second 2nm fab.0.59